According to the 2021 update of the diagnostic criteria for paraneoplastic neurological syndromes (PNSs) [6], LGI1 antibodies are classified as low risk for paraneoplastic association. The gene discussed is LGI1; the disease is paraneoplastic neurologic syndrome.